Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 0.88 |
| ▸ | CHAT | P28329 | 2/20 | 0.84 |
| ▸ | EP300 | Q09472 | 3/20 | 0.83 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.83 |
| ▸ | AURKA | O14965 | 2/20 | 0.83 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.83 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL60439 | 1.00 | NAA50 (0.88) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL29425568 | 1.00 | NAA50 (0.88) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL22361767 | 1.00 | NAA50 (0.88) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL28130999 | 1.00 | NAA50 (0.88) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL4358381 | 1.00 | NAA50 (0.88) | NAA50CHATEP300KAT5AURKA | |
| Phosphoric Acid SCHEMBL30705430 | 0.99 | NAA50 (0.87) | NAA50CHATEP300KAT5AURKA | |
| Methane SCHEMBL18038085 | 0.99 | NAA50 (0.87) | NAA50CHATEP300KAT5AURKA | |
| Methane SCHEMBL28198292 | 0.99 | NAA50 (0.87) | NAA50CHATEP300KAT5AURKA | |
| Acetic Acid SCHEMBL30464957 | 0.98 | NAA50 (0.87) | NAA50CHATEP300KAT5AURKA | |
| Acetic Acid SCHEMBL26923237 | 0.98 | NAA50 (0.87) | NAA50CHATEP300KAT5AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11692207-B2 | Enzymatic methods for butanol production | NEWPEK S.A. DE C.V. (MX) | 2023-07-04 | — | — | US | disclosed |
| US-20210222209-A1 | ENZYMATIC METHODS FOR BUTANOL PRODUCTION | NEWPEK S.A. DE C.V. (MX) | 2021-07-22 | — | — | US | disclosed |
| EP-3452606-A1 | ENZYMATIC METHODS FOR BUTANOL PRODUCTION | Newpek S.A. De C.V. (MX) | 2019-03-13 | — | — | EP | disclosed |
| US-9970037-B2 | Methods and materials for making simvastatin and related compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-15 | — | — | US | disclosed |
| WO-2017191483-A1 | ENZYMATIC METHODS FOR BUTANOL PRODUCTION | NEWPEK S.A. DE C.V. (MX) | 2017-11-09 | — | — | WO | disclosed |
| US-9694090-B2 | Process for preparing hyperpolarized substrates and method for MRI | BRACCO IMAGING S.P.A. (IT) | 2017-07-04 | — | — | US | disclosed |
| US-20170029790-A1 | VARIANT LovD POLYPEPTIDE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-02-02 | — | — | US | disclosed |
| US-20170022525-A1 | METHOD FOR PRODUCING METHACRYLIC ACID ESTER AND NOVEL METHACRYLIC ACID ESTER SYNTHETASE | MITSUBISHI RAYON CO., LTD. (JP) | 2017-01-26 | — | — | US | disclosed |
| US-9499803-B2 | Variant LovD polypeptide | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-22 | — | — | US | disclosed |
| US-20150218531-A1 | VARIANT LovD POLYPEPTIDE | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2015-08-06 | — | — | US | disclosed |
| US-20150203884-A1 | METHODS AND MATERIALS FOR MAKING SIMVASTATIN AND RELATED COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2015-07-23 | — | — | US | disclosed |
| US-8981056-B2 | Variant LovD polypeptide | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-03-17 | — | — | US | disclosed |
| US-8951754-B2 | Methods and materials for making simvastatin and related compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-02-10 | — | — | US | disclosed |
| US-20130096420-A1 | Process For Preparing Hyperpolarized Substrates And Method For MRI | BRACCO IMAGING S.P.A. (IT) | 2013-04-18 | — | — | US | disclosed |
| US-20120315680-A1 | METHODS AND MATERIALS FOR MAKING SIMVASTATIN AND RELATED COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120190038-A1 | LovD MUTANTS EXHIBITING IMPROVED PROPERTIES TOWARDS SIMVASTATIN SYNTHESIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-07-26 | — | — | US | disclosed |
| US-20090186358-A1 | Pathway Analysis of Cell Culture Phenotypes and Uses Thereof | WYETH (US) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029790-A1 | VARIANT LovD POLYPEPTIDE | FNTA, PCSK9, HMGCR | NAA50 2505/4885CHAT 4224/4885EP300 4595/4885 |
| US-20150218531-A1 | VARIANT LovD POLYPEPTIDE | FNTA, PCSK9, HMGCR | NAA50 2505/4885CHAT 4224/4885EP300 4595/4885 |
| US-20130096420-A1 | Process For Preparing Hyperpolarized Substrates And Method For MRI | HOGA1, HAMP, GLS2 | NAA50 868/4885CHAT 1380/4885EP300 4088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.